The Cysteinyl Leukotriene Receptor 1 pipeline drugs market research report outlays comprehensive information on the Cysteinyl Leukotriene Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cysteinyl Leukotriene Receptor 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Respiratory, Toxicology, Oncology, and Central Nervous System which include the indications Asthma, Allergic Rhinitis, Radiation Injury, Chemotherapy Induced Peripheral Neuropathy, Cervical Cancer, Endometrial Cancer, Alzheimer’s Disease, and Parkinson’s Disease. It also reviews key players involved in Cysteinyl Leukotriene Receptor 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Cysteinyl Leukotriene Receptor 1 pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Discovery stages are 2, 3, 1, and 1 respectively.
Cysteinyl Leukotriene Receptor 1 overview
Cysteinyl leukotriene receptor 1 (CYSLTR1) is a G protein-coupled receptor (GPCR) that plays a central role in the body’s response to leukotrienes, which are involved in inflammation and the contraction of smooth muscle in the airways. CYSLTR1 is a subtype of cysteinyl leukotriene receptors and is the primary target for the actions of leukotriene D4 (LTD4) and leukotriene C4 (LTC4).
For a complete picture of Cysteinyl Leukotriene Receptor 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
